Forecast

There is no analyst data available for this company.

News Go to news feed

Abivax back in focus among hedge funds after rally — obefazimod brings opportunities and risks

Abivax was a share-price driver in 2025 but is currently trading with high volatility and about 15 percent below the start of the year. The business model is concentrated on obefazimod for chronic inflammatory bowel diseases; a US approval application is planned for this year. Safety concerns over reported cancer cases were mitigated by additional data, after which analysts raised price targets and see, on average, upside potential of just over 60 percent; 7 of 8 analysts recommend the stock as a buy. Thanks to a capital increase, financing is secured until 2029, although losses are expected at least through 2027. » More on handelsblatt.com
Abivax obtains agreement with FDA on approval strategy for obefazimod

Abivax's share rose by 3.7% to €112.5, according to reports, after a pre-New Drug Application meeting with the FDA was successfully completed. The agency confirmed alignment on the submission strategy as well as on the content and format of the NDA dossier for obefazimod in moderate to severe ulcerative colitis. Abivax reiterated its intention to file the approval application by the end of 2026; analyst ratings remain largely positive. A favorable market environment supported the price movement. » More on de.investing.com
Abivax reaches agreement with FDA in pre-NDA process for Obefazimod

Abivax completed the pre-NDA meeting with the US FDA and received constructive feedback that led to agreement on the strategy and on the content and format of the regulatory submission. The company remains on track to file the NDA for Obefazimod by the end of 2026. The filing will rely on phase-3 results from the ABTECT program; Obefazimod is intended for adults with moderate to severe active ulcerative colitis and aims to stabilize the immune response. » More on de.investing.com

Financials

In the last quarter, Abivax had revenue of −2.02m€ and net profit of −235.32m€

(EUR)	Dec 2025	YoY
Revenue	−2.02m	-
Gross profit	−3.09m	-
Net profit	−235.32m	-
EBITDA	−155.96m	-

Fundamentals

Metric	Value
Market capitalization	+8.75b€
Number of shares	87.16m
52-week high/low	+139,00€ - +60,45€
Dividends	No
Beta	-0,23
P/E ratio	−20,79
PEG ratio	+0,34
P/B ratio	+15,33
P/S ratio	0,00

Company profile

ABIVAX Société Anonyme erforscht und optimiert Medikamente zur Behandlung von Entzündungskrankheiten, Infektionskrankheiten und Krebs in Frankreich. Zu den wichtigsten Produkten des Unternehmens gehören ABX464, das sich in klinischen Studien der Phase IIb zur Behandlung von Colitis ulcerosa und Morbus Crohn sowie von COVID-19 befindet, eine klinische Studie der Phase IIa zur Behandlung von rheumatoider Arthritis und eine klinische Studie der Phase IIa zur Behandlung von HIV-Patienten, die eine Virusremission anstreben. Außerdem entwickelt es ABX 196, einen Kandidaten zur Stärkung des Immunsystems, der sich in klinischen Phase-1/2-Studien zur Behandlung von Leberzellkrebs befindet. Darüber hinaus beteiligt sich das Unternehmen an Forschungsprogrammen zur Behandlung von Dengue-Fieber, Grippe und Respiratorischem Synzytialvirus. ABIVAX Société Anonyme hat Lizenzverträge mit dem französischen Nationalen Zentrum für wissenschaftliche Forschung, der Universität Montpellier und dem Institut Curie abgeschlossen. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Paris, Frankreich.